Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non–small-cell Lung Cancer
Authors:
- 1 November 2017
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 18 (6) , e433-e439
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (26460188, 17K08408)
This publication has 18 references indexed in Scilit:
- Effect of Sustained Elevated Gastric pH Levels on Gefitinib ExposureClinical Pharmacology in Drug Development, 2017
- Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphismEuropean Journal of Clinical Pharmacology, 2008
- Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)The Oncologist, 2005
- Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based TherapiesDrug Metabolism and Pharmacokinetics, 2005
- United States Food and Drug Administration Drug Approval SummaryClinical Cancer Research, 2004
- Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night‐time in different CYP2C19 genotype groupsAlimentary Pharmacology & Therapeutics, 2002
- A Rapid and Simple Detection of Genetic Defects Responsible for the Phenotypic Polymorphism of Cytochrome P450 2C19.Biological and Pharmaceutical Bulletin, 1999
- The cephalic and gastric phases of gastric secretion during H2-antagonist treatmentGastroenterology, 1991
- Effect of food on H2-receptor blockade in normal subjects and duodenal ulcer patients.Gut, 1990
- Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.Gut, 1987